Scarica l'app Stockscreener
1.65
9.27%
0.14
Dopo l'orario di chiusura:
1.65
Precedente Chiudi:
$1.51
Aprire:
$1.52
Volume 24 ore:
813.00K
Relative Volume:
0.93
Capitalizzazione di mercato:
$37.92M
Reddito:
-
Utile/perdita netta:
$-8.09M
Rapporto P/E:
-3.7896
EPS:
-0.4354
Flusso di cassa netto:
$-7.37M
1 W Prestazione:
+10.00%
1M Prestazione:
+35.25%
6M Prestazione:
+37.50%
1 anno Prestazione:
+18.28%
Intervallo 1D:
$1.52
$1.6777
Intervallo di 1 settimana:
$1.45
$1.6782
Portata 52W:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.65 | 34.70M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | Alliance Global Partners | Buy |
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
Oral Ebola drug gummies clear key ethics hurdle as Congo outbreak widens - Stock Titan
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Argus Leader
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NanoViricides Receives Outperform Rating and $6 Price Target from Noble Capital Markets - citybuzz -
NanoViricides Inc. (NNVC) Q2 2026 Earnings: EPS Beat but No Revenue; Stock Declines 1.01%Earnings Revision Upgrade - dars.gov.et
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
NanoViricides Price Target Announced at $6.00/Share by Noble Capital Markets - Moomoo
Noble Capital initiates NanoViricides stock with Outperform rating By Investing.com - Investing.com South Africa
Noble Financial Initiates Nanoviricides(NNVC.US) With Buy Rating, Announces Target Price $6 - Moomoo
NanoViricides Advances NV-387 Oral Gummies Toward Phase II Trial for Bundibugyo Ebola in DRC - citybuzz -
Noble Capital initiates NanoViricides stock with Outperform rating - Investing.com
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - ACCESS Newswire
NanoViricides moves NV-387 oral gummies toward DRC Ebola trial - Stock Titan
Enterprise value to revenue forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVCNanoViricides Inc Website Traffic and Mobile Apps Usage - Finviz
Price to book forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
Enterprise value to revenue forward of NanoViricides, Inc. – SWB:NV3P - TradingView
NNVC Q2 2026 Earnings: Narrower-than-Expected Loss as R&D Pipeline AdvancesOne-Time Gain Impact - DonanımHaber
Price to earnings forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock MovementOperating Income Trends - dars.gov.et
FDA rare pediatric disease designation could speed a measles drug review - Stock Titan
[EFFECT] NANOVIRICIDES, INC. SEC Filing - Stock Titan
NanoViricides (NNVC) Gains 3% as Stock Approaches Key ResistanceSupply Zone - DonanımHaber
NanoViricides, Inc. Actuals & Estimates (MUN:NV3P) - TradingView
NanoViricides, Inc. Actuals & Estimates (AMEX:NNVC) - TradingView
NanoViricides, Inc. Actuals & Estimates (LS:A2PSNF) - TradingView
NNVC Forecast — Price Target — Prediction for 2027 - TradingView
A2PSNF Forecast — Price Target — Prediction for 2027 - TradingView
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan - Yahoo Finance
NanoViricides Inc (NNVC) Institutional Confidence - TradingKey
NanoViricides Ships NV-387 to DRC for Phase II MPox Trial - MEXC
NanoViricides sends oral NV-387 to Congo for Phase II trial prep - Stock Titan
NNVC Q1 2026 Earnings: Narrower-than-expected loss and positive stock reactionEarnings Growth Forecast - dars.gov.et
NanoViricides Inc (NNVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NanoViricides Inc (NNVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Inc (NNVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nanoviricides | DEL AM: Others - Moomoo
NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial for Oral Antiviral NV-387 - citybuzz -
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NNVC Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentEarnings Expansion Phase - newsline.com
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatmentwith Superior Oral Administration and Escape Resistance Features Over Antibodies - ACCESS Newswire
NanoViricides pushes chewable Ebola drug trial as Congo outbreak escalates - Stock Titan
NanoViricides Files for $50 Million Mixed Shelf Offering - Moomoo
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides (NNVC) Edges Lower Within Narrow Trading RangePre-Earnings Momentum - newsline.com
NanoViricides (NNVC) Slides 3.6% as Selling Pressure IntensifiesInstitutional Buy Signals - The Legal Advocate
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):